Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Trans

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the an

Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonst

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN

SOUTH SAN FRANCISCO, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TN

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d

Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Exper

Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Re

Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy f

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCMBenefits

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of  MYBPC3-Associated HCM Benefit

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di

SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN

SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNY

Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-

Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PK

All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction C

Tenaya Therapeutics, Inc. (TNYA) came out with a quarterly loss of $0.09 per share in line with the

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.09) per share which missed the an

One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-A

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planne

SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: T

Belite Bio (NASDAQ: BLTE - Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report)

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the anal

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional D

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d

Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat

Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-

Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering

HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di

TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the anal

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneo

The U.S. Food and Drug Administration ("FDA") has placed a clinical hold on MyPEAKTM-1,Tenay

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores s

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit